REGENXBIO to Showcase Innovations at Upcoming Investor Conferences
REGENXBIO to Showcase Innovations at Upcoming Investor Conferences
REGENXBIO Inc., a leading player in the biotechnology sector, recently declared its participation in significant upcoming investor conferences. The company's presence at these events showcases its commitment to advancing gene therapy and highlights its robust pipeline of innovative treatments destined to change healthcare delivery.
Conference Participation Details
The first event is the 2026 RBC Capital Markets Global Healthcare Conference, scheduled for May 20, 2026, in New York, NY. REGENXBIO will participate in a fireside chat at 9:30 AM ET, providing investors a platform to engage with the company's leadership and gain insights into its future strategies and developments.
Following this, REGENXBIO will also partake in the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, again at 9:30 AM ET. This virtual format allows for broader access and engagement from the investment community and interested stakeholders.
Investors can access live webcasts of these discussions through the Investors section of REGENXBIO's website, with recorded replays available for about 30 days post-event. This not only ensures transparency but also accommodates those unable to attend the live sessions.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has been at the forefront of pioneering AAV (Adeno-Associated Virus) gene therapy. The company's mission is to transform lives through the curative potential of gene therapies. REGENXBIO is advancing an impressive range of late-stage treatment candidates for rare and serious diseases, particularly in the realm of retinal conditions.
The pipeline includes:
- - RGX-202 for Duchenne Muscular Dystrophy
- - clemidsogene lanparvovec (RGX-121) for MPS II in collaboration with Nippon Shinyaku
- - RGX-111 targeting MPS I, also in partnership with Nippon Shinyaku
- - surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie
With thousands of patients having benefited from REGENXBIO's gene therapies, including Novartis’ acclaimed ZOLGENSMA, the company stands as a beacon of hope for future healthcare advancements. Their investigational therapies hold the potential to transform treatment paradigms and offer new solutions to those suffering from genetic disorders.
In summary, REGENXBIO’s participation in these upcoming conferences underscores its commitment to open dialogue with investors while simultaneously highlighting its advancements in gene therapy—a testament to the crucial role that innovative biotechnology plays in shaping future healthcare solutions.
For additional information about REGENXBIO and its groundbreaking work in gene therapy, please visit WWW.REGENXBIO.COM.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.